Locations/Subsidiaries
Benchmark Dental Laboratory,
Lombard Lodge, Worcester Road, Stourport on Severn,
Worcestershire,
United Kingdom
Fax: 44 1299 825577
Aesthetic Dental Services Ltd.,
201 Bristol Avenue, Bispham,
Blackpool,
United Kingdom
Fax: 44 1253 500592
112 Wetherby Road,
Harrogate,
North Yorkshire ,
United Kingdom
Fax: 44 1423 880036
Aesthetic Dental Services Ltd.,
Salter Road, Eastfield,
Scarborough,
United Kingdom
Fax: 44 1273 581345
Benchmark Dental Laboratory,
The Library, New Greenham Park,
Newbury,
Berkshire,
United Kingdom
Fax: 019 0284 5476
Aesthetic Dental Lab,
19 Billbrook Road, Codsall,
Wolverhampton,
West Midlands,
United Kingdom
Fax: 44 1902 845476
GAC Dental Laboratory,
Chalvington House, Dittons Park,
Eastbourne,
East Sussex ,
United Kingdom
Fax: 44 1323 487736
A.R.T,
Highridge, 51 Wisewood Road, Hillsborough,
Sheffield,
United Kingdom
Fax: 44 1142 333254
Benchmark Dental Laboratory,
Renwick House, Brixham Road,
Paignton,
United Kingdom
Fax: 44 1803 664273
Riley Dental Laboratory,
High Holburn Road, Codnor Business Park,
Ripley,
United Kingdom
Fax: 44 1773 570978
Ramsey Dental Laboratory,
Concorde House, Westbourne Road,
Ramsey,
United Kingdom
Fax: 44 1624 814284
Quality Smiles,
Unit 8, Phoenix Industrial Park, Chickenhall Lane,
Eastleigh,
United Kingdom
Fax: 44 2380 620996
David Bird Laboratories Ltd.,
Unit 7/8/9, Stephenson Court, Barrington Industrial Estate,
Bedlington,
Northumberland,
United Kingdom
Fax: 44 1670 531501
Benchmark Dental Laboratory,
112-118 Station Road,
Chinnor,
United Kingdom
Fax: 44 1844 353643
Intelligence
Discovery Innovation – Productive Partnering for Shared Success
Published by Kinapse
White Papers
ALSCG Revenue Contract Management System Implementations
Published by Alliance Life Sciences Consulting Group, Inc.
White Papers
Interview with Dr David Orloff
Published by Medpace
White Papers
Pharmacovigilance
Published by A-Consult
White Papers
Buy the latest industry research online today!
Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Reports Buy online from $3500
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Reports Buy online from $3500
Suppliers Directory
Avicor - Affinity Chromatography and Chemical Microarray Drug Discovery Services
Avicor provides key technologies for the early phase of drug discovery with chemical microarrays, chemoproteomics and interaction-based HTS.
Suppliers
Pharmaceutical Development Services - Pharmaceutical, Regulatory and Medical Device Consultancy
Pharmaceutical Development Services (PDS) is a pharmaceutical and regulatory consultancy serving the pharmaceutical, biopharmaceutical, medical device and cosmetic industries. We provide expert advice on drug development and production strategy including the development, supply and regulatory control of new and existing pharmaceutical products.
Suppliers
Glycotope - GlycoEngineering and Immunotherapeutics
Founded in 2001, Glycotope is a leading biopharmaceutical company in the fields of glycomics and immunotherapeutics that has developed a unique and regulatory approved platform technology for the development and production of NBEs and improved second generation biopharmaceuticals / BioBetters.
Suppliers
Optima Group pharma - Filling and Packaging Machines for Syringes, Vials, Bottles and Carpules Products
Optima Group Pharma consists of four top-quality brands: Inova, Klee, Kugler and Metall + Plastic. Thanks to years of specializing, the Optima Group Pharma offers a comprehensive, cutting-edge range of products. This includes the filling and packaging of pharmaceutical liquids and powders, combined production and packaging lines for medical/ pharmaceutical products as well as automation and laboratory processes. Additionally the designing, manufacturing, installation and validation of state-of-the-art isolation and containment technology are also part of the portfolio.
Suppliers
Production & Manufacturing
Fine & Speciality Chemicals
Manufacturing
Process & Production
OTC
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
